Takeda Pharmaceutical/$TAK
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Takeda Pharmaceutical
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4.6 trillion in fiscal 2024. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with over 50% derived from the US, 20% from Japan, 20% from Europe and Canada.
Ticker
$TAK
Sector
Primary listing
NYSE
Employees
47,455
Headquarters
Tokyo, Japan
Website
TAK Metrics
BasicAdvanced
$43B
102.61
$0.13
0.03
$0.54
4.03%
Price and volume
Market cap
$43B
Beta
0.03
52-week high
$15.69
52-week low
$12.80
Average daily volume
2.9M
Dividend rate
$0.54
Financial strength
Current ratio
1.365
Quick ratio
0.647
Long term debt to equity
68.669
Total debt to equity
65.136
Dividend payout ratio (TTM)
935.06%
Interest coverage (TTM)
2.30%
Profitability
EBITDA (TTM)
7,376.657
Gross margin (TTM)
64.80%
Net profit margin (TTM)
0.75%
Operating margin (TTM)
11.01%
Effective tax rate (TTM)
66.00%
Revenue per employee (TTM)
$603,150
Management effectiveness
Return on assets (TTM)
2.09%
Return on equity (TTM)
0.47%
Valuation
Price to earnings (TTM)
102.61
Price to revenue (TTM)
0.755
Price to book
0.93
Price to tangible book (TTM)
-4.13
Price to free cash flow (TTM)
3.616
Free cash flow yield (TTM)
27.65%
Free cash flow per share (TTM)
3.791
Dividend yield (TTM)
3.96%
Forward dividend yield
4.03%
Growth
Revenue change (TTM)
-2.84%
Earnings per share change (TTM)
-88.67%
3-year revenue growth (CAGR)
5.61%
10-year revenue growth (CAGR)
9.21%
3-year earnings per share growth (CAGR)
-46.67%
10-year earnings per share growth (CAGR)
-20.11%
3-year dividend per share growth (CAGR)
3.23%
10-year dividend per share growth (CAGR)
0.96%
What the Analysts think about TAK
Analyst ratings (Buy, Hold, Sell) for Takeda Pharmaceutical stock.
Bulls say / Bears say
Takeda’s $1.2 billion upfront payment and as much as $10.2 billion in milestone payments from its Innovent Biologics deal will bring a significant cash boost in the short term and strengthen its oncology pipeline with late-stage drug candidates (Reuters)
Refocusing from cell therapy to small molecules, biologics, and antibody-drug conjugates should speed up the time-to-market for key drugs by directing resources toward more scalable treatments that can reach patients faster (Reuters)
Setting up global clinical trials in India and expanding the Bengaluru innovation center to 750 employees leverages cost-effective R&D and a more diverse trial base, which could lower expenses and shorten development timelines (Reuters)
Recognition of a 58 billion yen impairment loss on its gamma delta T-cell therapy platform in Q2 FY2025 highlights the sunk costs from exiting cell therapy, impacting profitability in the near term (Reuters)
Halting cell therapy programs reduces Takeda’s long-term pipeline diversification in immuno-oncology and may allow competitors to gain ground in cell-based therapies (Reuters)
Relying on regulatory approvals in India, such as for its dengue vaccine, brings execution risk; potential delays or setbacks by Indian authorities could limit expected revenue growth in a key emerging market (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 6 Nov 2025.
TAK Financial Performance
Revenues and expenses
TAK News
AllArticlesVideos
Takeda Presents New Data Showing Mezagitamab (TAK-079) Sustained Effect on Kidney Function 18 Months After Treatment in Primary IgA Nephropathy
Business Wire4 days ago
New Phase 3 Data Show Takeda's Dengue Vaccine Delivers 7 Years of Sustained Protection Against Infection and Hospitalization
Business Wire1 week ago
Takeda Reports First Half FY2025 Results, with Business Fundamentals Tracking as Planned. Updates Full Year Outlook to Reflect FX Impact and Pipeline Impairment.
Business Wire2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Takeda Pharmaceutical stock?
Takeda Pharmaceutical (TAK) has a market cap of $43B as of November 11, 2025.
What is the P/E ratio for Takeda Pharmaceutical stock?
The price to earnings (P/E) ratio for Takeda Pharmaceutical (TAK) stock is 102.61 as of November 11, 2025.
Does Takeda Pharmaceutical stock pay dividends?
Yes, the Takeda Pharmaceutical (TAK) stock pays dividends to shareholders. As of November 11, 2025, the dividend rate is $0.54312 and the yield is 4.03%. Takeda Pharmaceutical has a payout ratio of 935.06% on a trailing twelve-month basis.
When is the next Takeda Pharmaceutical dividend payment date?
The next Takeda Pharmaceutical (TAK) dividend payment date is unconfirmed.
What is the beta indicator for Takeda Pharmaceutical?
Takeda Pharmaceutical (TAK) has a beta rating of 0.03. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.